Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of recombinant human erythropoietin (Fc) fusion protein injection for anemia in dialysis patients with chronic kidney disease
CTR20213101Phase 2Completed
- Sponsor
- Dongguan Taili Biological Engineering
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human erythropoietin Fc fusion protein in Uraemic Anaemia, sponsored by Dongguan Taili Biological Engineering. Started Jun 2022; status: completed.
02
Drugs
recombinant human erythropoietin Fc fusion protein
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on CTR20213101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213101.